The preclinical development experts at Sprint Bioscience started the second half of the year by signing the company’s largest licensing agreement to date in a deal concerning drug candidate Vps34. The company is now initiating marketing for the next project in line. BioStock spoke to the company’s Chief Scientific Officer, Martin Andersson, to find out more about the project.
Read the full article at biostock.se:
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se